Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

9.690 -0.030 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Breaking Down Dynavax Technologies: 5 Analysts Share Their Views
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
Earnings Scheduled For May 6, 2025
Via Benzinga
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
From Deep Track Capital, LP
Via Business Wire
Deep Dive Into Dynavax Technologies Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Where Dynavax Technologies Stands With Analysts
Via Benzinga
Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer
From Deep Track Capital, LP
Via Business Wire
Evaluating DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:DVAX): Why DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) is Poised for High Growth. 
Via Chartmill
Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors
From Deep Track Capital, LP
Via Business Wire
Insights into Dynavax Technologies's Upcoming Earnings
Via Benzinga
Assessing Dynavax Technologies: Insights From 4 Financial Analysts
Via Benzinga
Dynavax Technologies: Q4 Earnings Insights
Via Benzinga
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
DVAX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
From Deep Track Capital, LP
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand. 
Via Benzinga
This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript
DVAX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
From Glancy Prongay & Murray LLP
Via Business Wire
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript
DVAX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024
DVAX stock results show that Dynavax Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter. 
Via Benzinga
Exposures Product Safety
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
DVAX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
DVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024
DVAX stock results show that Dynavax Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
DVAX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
3 Stocks Set to Soar 68% to 200% Higher
Analyst stock picks for outsized growth potential mean these companies should handily outperform the market averages. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.